Search

Your search keyword '"Antonio Benítez Roldán"' showing total 2 results
Start Over Author "Antonio Benítez Roldán" Journal revista espanola de enfermedades digestivas
2 results on '"Antonio Benítez Roldán"'

1. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months

Author

Maria-Fernanda Guerra-Veloz, Juan-María Vázquez-Morón, María Belvis-Jiménez, Héctor Pallarés-Manrique, Teresa Valdés-Delgado, Luisa Castro-Laria, Belén Maldonado-Pérez, Antonio Benítez-Roldán, Raúl Perea-Amarillo, Vicente Merino, Ángel Caunedo-Álvarez, Ángel Vilches-Arenas, and Federico Argüelles-Arias

Subjects
Crohn's disease, Ulcerative colitis, Inflammatory bowel disease, Biosimilar agent, CT-P13, Infliximab, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

ABSTRACT Background and aims: infliximab has changed the natural history of inflammatory bowel disease (IBD). The advent of biosimilar treatments such as CT-P13 will hopefully improve the availability of biological therapies. Data with regard to drug switching are currently limited. The objective of the study was to assess the effectiveness and safety of switching from the reference product (RP), infliximab, to CT-P13 in patients with IBD. Methods: this was a multicenter prospective observational study in patients with Crohn's disease (CD) and ulcerative colitis (UC). All patients had switched from infliximab RP (Remicade(r)) to CT-P13 treatment and were followed up for 12 months. The efficacy endpoint was the change in clinical remission assessed at 0 and 12 months, according to the Harvey-Bradshaw score and partial Mayo score for patients with CD and UC, respectively. Adverse events were monitored and recorded throughout the study. Results: a total of 167 patients (116 CD/51 UC) were included; 88.8% (103/116) of patients with CD were in remission at the time of the drug switch and 69.7% were in remission at 12 months. The Harvey-Bradshaw (HB) score significantly changed at 12 months (p = 0.001); 84.3% (43/51) of patients with UC were in remission at the time of the drug switch and 76.7% were in remission at 12 months. No significant changes in the median partial Mayo score (p = 0.87) were observed at 12 months. Serious adverse events related to medication were reported in 12/167 (7.2%) cases. Conclusion: switching from infliximab RP to CT-P13 is safe and effective at 12 months. The loss of efficacy at 12 months was 15.7%.

Published
2018
Full Text
View/download PDF

2. Index of the Mayo Endoscopy and Ulcerative Colitis Endoscopy Index of Severity: are they equally valid?

Author

Victoria Alejandra Jiménez García, Ángel Caunedo Álvarez, Pedro Hergueta-Delgado, Luisa Castro Laria, María Dolores Galván Fernández, Blas José Gómez Rodríguez, María Belvis Jiménez, Antonio Benítez Roldán, Belén Maldonado Pérez, María Fernanda Guerra Veloz, Manuel Rodríguez-Téllez, Cristina Castro Márquez, Federico Argüelles Arias, Reyes Aparcero López, Antonio Garrido Serrano, María Luisa Morales Barroso, and Rafael Romero Castro

Subjects
Cohort Studies, Observer Variation, business.industry, Gastroenterology, Humans, Medicine, Colitis, Ulcerative, Colonoscopy, General Medicine, Middle Aged, business, Severity of Illness Index, Humanities
Abstract

Introduccion: la endoscopia tiene un papel fundamental en el manejo de los pacientes con colitis ulcerosa (CU), ya que permite la visualizacion y evaluacion de la gravedad de la enfermedad. No obstante, dicha evaluacion no es siempre algo objetivo, por lo que se han desarrollado diferentes escalas que pretenden homogeneizar los hallazgos. Objetico: el objetivo del estudio fue evaluar la variabilidad interobservador entre el Indice de Mayo Endoscopico (IME) y el Indice de Severidad Endoscopica de la Colitis Ulcerosa (UCEIS), al analizar la gravedad de las lesiones endoscopicas en pacientes con CU. El objetivo secundario fue analizar si la preparacion catartica afectaba al grado de concordancia entre los endoscopistas. Material y metodos: se trata de un estudio observacional comparativo de una unica cohorte a la cual se realiza una colonoscopia bajo guia de practica clinica habitual a pacientes con CU y se estadifica segun el IME y el UCEIS por tres endoscopistas expertos. Para valorar el grado de correlacion interobservador se utilizaron el indice de Kappa para el IME y el coeficiente de correlacion intraclase para el UCEIS. Se incluyeron 67 pacientes, con edad media de 51 anos (DE ± 16,7) e indice de Mayo clinico medio de 3,07 (DE ± 2,54). Resultados: el indice de Kappa ponderado entre los endoscopistas A y B para el IME fue de 0,8; entre el A y el C, de 0,52; y entre el B y el C, de 0,49. Para el UCEIS, el coeficiente de correlacion intraclase fue del 0,922 entre los tres endoscopistas (IC 95 %: 0,832-0,959). Se encontro una mejor correlacion interobservador cuando la preparacion catartica era ≥ 8 segun la escala de Boston. Conclusion: existe, por tanto, una superior correlacion entre los diferentes endoscopistas para el UCEIS que para el IME, por lo que deberia ser considerado como el mejor indice a utilizar en la practica clinica. Una buena preparacion catartica es importante para mejorar la correlacion interobservador.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results